Evidence map›Paper›PMID 33046271›Full record

ArticleEuropean urology2021

The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management.

Stanley Weng, Renzo G DiNatale, Andrew Silagy, Roy Mano, Kyrollis Attalla, Mahyar Kashani, Kate Weiss, Nicole E Benfante, Andrew G Winer, Jonathan A Coleman and 5 more

Open access · greenAbstract read
In one paragraph

Article in European urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Contemporary review of papillary renal cell carcinoma-current state and future directions.Virchows Archiv : an international journal of pathology · 2024
    Review
  8. Mutated ASXL1 upregulates mTOR expression in renal cell carcinoma with fibromyomatous stroma.Virchows Archiv : an international journal of pathology · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Stanley WengUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
Renzo G DiNataleUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Computational Oncology, Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew SilagyUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Roy ManoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kyrollis AttallaUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mahyar KashaniDepartment of Urology, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
Kate WeissUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nicole E BenfanteUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew G WinerDepartment of Urology, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
Jonathan A ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Victor E ReuterDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paul RussoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ed ReznikComputational Oncology, Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Satish K TickooDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: tickoos@mskcc.org.
A Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hakimia@mskcc.org.
Memorial Sloan Kettering Cancer Center · USSUNY Downstate Health Sciences University · USMolecular Oncology (United States) · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
UROLOGY ONCOLOGY RESEARCH TRAINING GRANTT32CA082088 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Brett Stewart Carver · 1999 to 2026
$7.1M
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA082088
6 · The paper itself

Abstract

backgroundClear cell papillary renal cell carcinoma (CCPRCC) is a recently described tumor entity. Several questions remain about its epidemiology, molecular features, and clinical behavior.

objectiveTo comprehensively evaluate clinicopathologic and molecular features of CCPRCC, and compare it with more common kidney cancer subtypes. DESIGN, SETTING, AND

participantsWe identified 89 CCPRCC patients and compared their clinicopathologic features with 1120 localized clear cell renal cell carcinoma (ccRCC) and 129 type 1 papillary renal cell carcinoma (pRCC) patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Nonparametric statistical testing was used to compare relevant features between tumor types. Overall, cancer-specific survival (CSS) and metastasis-free survival estimates were calculated from initial diagnosis using the Kaplan-Meier method. Patients with ipsilateral multifocal disease were explored further. A subset of CCPRCC tumors underwent genomic analysis and were compared with other RCC subtypes. RESULTS AND LIMITATIONS: A higher proportion of female (45% vs 32%) and African-American (19% vs 3%) patients were observed in the CCPRCC cohort than in the ccRCC and pRCC cohorts. CCPRCC tumors also had increased odds of presenting with additional ipsilateral masses (odds ratio [OR]: 4.41 [confidence interval {CI}: 2.34, 8.15], p < 0.001) and bilateral disease (OR: 4.80 [CI: 2.40, 9.59], p < 0.001) compared with ccRCC tumors. On molecular analysis, CCPRCC tumors showed fewer somatic aberrations and a greater degree of mitochondrial DNA depletion. In multifocal CCPRCC tumors, histologic concordance among the different renal cell carcinoma masses was estimated at 44% (7/16), and none of the individuals presenting exclusively with CCPRCC tumors developed metastatic disease after 5 yr. In contrast, multifocal tumors with CCPRCC and other nonconcordant histologies were more likely to experience adverse outcomes (CSS, log rank p = 0.034).

conclusionsCCPRCC is characterized by distinct molecular and epidemiologic features that could be used to refine current diagnostic approaches. Although their clinical course is generally indolent, multifocal CCPRCC tumors represent a unique diagnostic challenge. In this context, single-mass biopsies could miss concomitant aggressive disease, with a potential negative impact on patient outcomes. Furthermore, high discordance rates in multifocal CCPRCC tumors have important clinical implications in management. PATIENT SUMMARY: We explored the molecular and clinical features of clear cell papillary renal cell carcinoma (CCPRCC) relative to other kidney cancer subtypes. While CCPRCC generally conveys a good prognosis, additional caution should be taken when it is diagnosed using biopsy if multiple kidney masses are present.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsBiopsyFemaleHumansRetrospective StudiesClear cell papillaryDNA copy numberGenomicsRenal cell carcinoma

Identifiers

PMID33046271
PMCPMC8327325
OpenAlexW3092227785

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.